Mendelian randomization evaluation of causal effects of fibrinogen on incident coronary heart disease.
Cavin K Ward-CavinessPaul S de VriesKerri L WigginsJennifer E HuffmanLisa R YanekLawrence F BielakFranco GiulianiniXiuqing GuoMarcus Edi KleberTim KacprowskiStefan GroßAstrid PetersmanGeorge Davey SmithFernando Pires HartwigJack BowdenGibran HemaniMartina Müller-NuraysidKonstantin StrauchWolfgang KoenigMelanie WaldenbergerThomas MeitingerNathan D PankratzEric BoerwinkleWeihong TangYi-Ping FuAndrew D JohnsonCi SongMoniek P M de MaatAndré G UitterlindenOscar H FrancoJennifer A BrodyBarbara McKnightYii-Der Ida ChenBruce M PsatyRasika A MathiasDiane M BeckerPatricia A PeyserJennifer A SmithSuzette J BielinskiPaul M RidkerKent D TaylorJie YaoRussell TracyGraciela DelgadoStella TrompetNaveed SattarJ Wouter JukemaLewis C BeckerSharon L R KardiaJerome I RotterWinfried MärzMarcus DörrDaniel I ChasmanAbbas DehghanChristopher J O'DonnellNicholas L SmithAnnette PetersAlanna C MorrisonPublished in: PloS one (2019)
A small causal effect of fibrinogen on CHD is observed using multi-variant MR approaches which account for pleiotropy, but not single variant MR approaches. Taken together, results indicate that even with large sample sizes and multi-variant approaches MR analyses still cannot exclude the null when estimating the causal effect of fibrinogen on CHD, but that any potential causal effect is likely to be much smaller than observed in epidemiological studies.